Financial Performance - MapLight Therapeutics reported a net loss of $29.4 million for Q3 2025, compared to a net loss of $19.0 million in Q3 2024, reflecting an increase of 55.6% year-over-year[12]. - Total operating expenses for Q3 2025 were $31.5 million, compared to $20.9 million in Q3 2024, marking a 50.8% increase[15]. - General and administrative expenses for Q3 2025 were $4.4 million, slightly higher than $4.1 million in Q3 2024, reflecting increased legal and consulting fees[12]. Research and Development - Research and development expenses for Q3 2025 were $27.1 million, up from $16.8 million in Q3 2024, indicating a 61.5% increase primarily due to higher clinical trial costs[12]. - Topline results from the Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia are expected in the second half of 2026, with 300 participants enrolled[6]. - Enrollment in the Phase 2 IRIS study for ML-004 in Autism Spectrum Disorder has been completed, with topline results anticipated in the second half of 2026[9]. - The company expects to complete IND-enabling studies for ML-021 in the second half of 2026, targeting motor deficits in Parkinson's Disease[9]. Capital and Assets - The company raised $296.5 million in gross proceeds from its initial public offering and concurrent private placement in October 2025, with net proceeds of $269.8 million after expenses[5]. - Cash, cash equivalents, and short-term investments totaled $227.2 million as of September 30, 2025, sufficient to fund operations through 2027[5]. - The company ended Q3 2025 with total assets of $257.2 million, up from $136.9 million at the end of 2024[17].

Core Insights - MapLight Therapeutics reported significant progress in its clinical pipeline and financial results for Q3 2025, highlighting advancements in treatments for central nervous system disorders [2][3][4]. Financial Highlights - The company raised $296.5 million in gross proceeds from its initial public offering (IPO) and concurrent private placement in October 2025, with net proceeds of $269.8 million after expenses [4][6]. - As of September 30, 2025, MapLight had $227.2 million in cash, cash equivalents, and short-term investments, which are expected to fund operations through 2027 [10][15]. - Research and development expenses for Q3 2025 were $27.1 million, up from $16.8 million in Q3 2024, primarily due to increased clinical trial costs [10][13]. - The net loss for Q3 2025 was $29.4 million, compared to a net loss of $19.0 million in Q3 2024 [10][13]. Clinical Development Progress - The Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia is expected to yield topline results in the second half of 2026, with 300 participants enrolled [4][5]. - The Phase 2 VISTA trial for ML-007C-MA in Alzheimer's disease psychosis is anticipated to report topline results in the second half of 2027, also enrolling 300 participants [4][5]. - Enrollment in the Phase 2 IRIS study for ML-004, targeting autism spectrum disorder, has been completed, with results expected in the second half of 2026 [4][5]. - The company plans to complete IND-enabling studies for ML-021, aimed at treating motor deficits in Parkinson's disease, in the second half of 2026 [5]. Company Overview - MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for patients with debilitating central nervous system disorders, founded by leaders in psychiatry and neuroscience [8].

Corporate Presentation December 4, 2025 Innovation-Driven Company Globally Recognized Scientific Founders Established in 2018 to >100 Employees Broad & Diversified Product Pipeline Safe Harbor and Forward-Looking Statements This presentation and any accompanying oral commentary have been prepared by MapLight Therapeutics, Inc. ("MapLight", "we," "us," "our," the "Company", or similar terms) for informational purposes only and not for any other purpose. This presentation contains trademarks, service marks, t ...

Core Points - MapLight Therapeutics, Inc. has successfully closed its initial public offering (IPO) of 16,962,500 shares at a price of $17.00 per share, including the full exercise of underwriters' option for an additional 2,212,500 shares [1][3] - The company also completed a concurrent private placement of 476,707 shares at the IPO price to affiliates of Goldman Sachs, which was not registered under the Securities Act [2][3] - The total gross proceeds from both the IPO and private placement amounted to $296.3 million before deducting underwriting discounts and expenses [3] Company Overview - MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on treating patients with central nervous system disorders [6] - The company was founded by leaders in psychiatry and neuroscience to develop circuit-specific pharmacotherapies [6] - Its lead product candidate, ML-007C-MA, is currently in Phase 2 clinical trials for schizophrenia and Alzheimer's disease psychosis [6]

Core Viewpoint - Maplight Therapeutics (MPLT.US) has successfully launched on the US stock market, with shares rising over 15.8% to $19.7, following an IPO price of $17, indicating strong market interest in its innovative approach to treating central nervous system disorders [1] Company Overview - Maplight Therapeutics was founded by renowned leaders in psychiatry and neuroscience, focusing on addressing the lack of targeted drug therapies for specific neural circuits in patients [1] - The company has developed a platform capable of identifying neural circuits causally related to diseases, allowing for targeted therapeutic modulation [1] Product Pipeline - Maplight has created a range of candidate products aimed at treating some of the most challenging central nervous system diseases, including schizophrenia, Alzheimer's disease, and autism spectrum disorders [1]

Core Insights - Maplight Therapeutics (MPLT.US) has successfully launched on the US stock market, with shares rising over 15.8% to $19.7, after an IPO price of $17 [1] Company Overview - Maplight Therapeutics was founded by renowned leaders in psychiatry and neuroscience, focusing on addressing the lack of targeted drug therapies for specific neural circuits [1] - The company claims its platform can identify neural circuits causally related to diseases and provide therapeutic modulation for these circuits [1] Product Development - Maplight has developed a range of candidate products aimed at treating some of the most challenging central nervous system diseases, including schizophrenia, Alzheimer's disease, and autism spectrum disorders [1]

Core Insights - MapLight Therapeutics shares opened 11.8% above their offer price during their Nasdaq debut, indicating strong market interest and demand for the company's stock [1] - The initial valuation of MapLight Therapeutics reached $787 million, reflecting investor confidence in the drug developer's potential [1] Company Summary - MapLight Therapeutics is a drug developer that has recently gone public, showcasing its growth potential through a successful Nasdaq debut [1] - The company's stock performance on its first day suggests a positive reception from investors, which may indicate future opportunities for capital raising and expansion [1]

Core Points - MapLight Therapeutics, Inc. has priced its initial public offering (IPO) at $17.00 per share for 14,750,000 shares, with an additional option for underwriters to purchase 2,212,500 shares [1][2] - The total expected gross proceeds from the IPO and a concurrent private placement are approximately $258.9 million, excluding underwriters' options and expenses [2] - The shares are set to begin trading on the Nasdaq Global Market under the symbol "MPLT" on October 27, 2025, with the offering expected to close on October 28, 2025 [3] Company Overview - MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on central nervous system disorders, founded by leaders in psychiatry and neuroscience [7] - The company's lead product candidate, ML-007C-MA, is currently in Phase 2 clinical trials for treating schizophrenia and Alzheimer's disease psychosis [7]

Core Insights - MapLight Therapeutics plans to raise approximately $251 million through an initial public offering (IPO), which would position the biotech among the top public listings in the sector for 2025 [1] - The company intends to offer 14,750,000 shares at a price of $17.00 per share, and will be listed on the Nasdaq Global Market under the symbol "MPLT" [1] - MapLight has utilized a regulatory provision to facilitate the IPO process despite the ongoing US government shutdown, which has affected the Securities and Exchange Commission's (SEC) operations [1][2] Fund Allocation - If the IPO proceeds as planned, the majority of the funds will be allocated to the development of ML-007C-MA, its lead candidate for schizophrenia, with up to $120 million earmarked for a Phase II study involving 300 patients [3] - An additional $70 million will be dedicated to a separate Phase II study of ML-007C-MA for Alzheimer's disease psychosis, while the remaining funds will support other pipeline projects, including candidates for autism spectrum disorder and preclinical assets for Parkinson's disease and hyperactivity disorders [4] Financial Backing and Market Context - MapLight has garnered interest from major pharmaceutical companies, including Sanofi and Novo Holdings, and previously raised $372.5 million in a Series D financing round [5] - The company currently has $60.5 million in cash, indicating a need for the IPO to fund ongoing development efforts [5] - The IPO follows a successful public offering by LB Pharmaceuticals, which raised $285 million in September, marking a positive trend in the biotech IPO landscape [6]

Group 1 - MapLight Therapeutics, a biotechnology company based in Redwood City, California, plans to raise approximately $251 million through an IPO by issuing 14.8 million shares at a price of $17 per share, resulting in a fully diluted market capitalization of about $820 million [1] - The company focuses on developing innovative therapies for neuropsychiatric and central nervous system (CNS) diseases, with its main candidate drug ML-007C-MA aimed at treating schizophrenia and Alzheimer's disease psychosis (ADP) [2][3] - T. Rowe Price has committed to purchasing approximately $40 million worth of shares, representing 16% of the total offering, and MapLight plans to conduct an additional $8 million private placement with Goldman Sachs [1] Group 2 - Due to the current U.S. government shutdown, the SEC has paused the formal review of registration statements, prompting MapLight to utilize a rare provision under the Securities Act of 1933 to advance its listing process [2] - The company intends to price its shares 20 days after filing, but may reassess its strategy if the SEC resumes normal operations before October 26 [2] - MapLight was founded in 2018 and plans to list on NASDAQ under the ticker "MPLT," with Morgan Stanley, Jefferies, Leerink Partners, and Stifel serving as joint underwriters for the offering [3]